Fig. 2From: Long-term efficacy of anti-IL-4 receptor antibody in a patient with aspirin-exacerbated respiratory disease and IgG4-related diseaseChanges in serum IgG4 levels (black circle) and peripheral plasmablast counts (grey diamond) during the treatment course. Dupilumab was initially started at 2 weeks-intervals and maintained a 4 weeks-intervals. The patient was able to become free of oral corticosteroid (OCS) from May 2020. RES: Reslizumab; OCS: oral corticosteroidBack to article page